About New Rhein
New Rhein applies a private equity investment approach to life sciences venture capital investing, with a focus on later-stage, de-risked assets with proven clinical safety and efficacy. We believe that product development execution and strategic exits are the most important drivers of investment returns. Our goal is to develop products that deliver important health benefits to patients, compelling economic value to payors, and generate capital gains through strategic exits.
Trans-Atlantic Platform
Corporate Offices
Portfolio Offices
Strategic Partnerships
Office Locations
Two Logan Square
Suite 1930
Philadelphia, PA 19103
Blokhuisstraat 47j
2800 Mechelen, Belgium
Our team
New Rhein’s managing partners have complementary backgrounds in R&D, Commercialization, Organization Capability Building and M&A. With over 65 years of combined life sciences industry experience our team is uniquely positioned to find the right products, bring them to market and drive exits that benefit our investors.
Our portfolio companies
New Rhein Funds II and III have invested in six companies developing proprietary drug/device platforms for pain management, BPH, weight management, but also a CDMO or next-generation soft-mist device etc
